Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael Demicco"'
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 10 (2017)
Background: Plecanatide, with the exception of a single amino acid replacement, is identical to human uroguanylin and is approved in the United States for adults with chronic idiopathic constipation (CIC). This double-blind, placebo-controlled, phase
Externí odkaz:
https://doaj.org/article/13d128ce35eb4e6f9b8dcd50d1742408
Autor:
Stuart C. Gordon, Lisa Moorehead, Eric Lawitz, William E. Delaney, Michael Demicco, John G. McHutchison, Maribel Rodriguez-Torres, Jenny C. Yang, J. Hill, Hongmei Mo, Thomas Marbury, Anita Mathias
Publikováno v:
Antiviral Therapy. 18:311-319
Background GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1 replicons. Methods The safety, pharmacokinetics and antiviral efficacy of GS-9451 were evaluated in a Phase I study in t
Autor:
Juan Carlos Lopez-Talavera, Ronald Goldwater, Thomas Marbury, Michael Charlton, Dennis Hernandez, Walter K. Kraft, Eric Lawitz, Amy K. Sheaffer, Claudio Pasquinelli, David Wright, Maribel Rodriguez-Torres, Shu-Pang Huang, Michael DeMicco, Timothy Eley, Dennis M. Grasela, Pamela Sheridan, Criselda Villegas, Paul Michael Scola, Katrina Sandy, Anna Persson, Fiona McPhee
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:1838-1844
Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-65003
Autor:
Sayed S. Khatami, Wayne L. Harper, Gina S. Kwak, Lucy Clayton, Jeff Pilot, Pradeep Bekal, Michael DeMicco, Barrett G. Levesque, Kenneth E. Smith, Michael P. Epstein, Joseph B. Henderson, Mahmoud Mosli, Thomas E. Jarrett, Vipul Jairath, Kenneth L. Kelln, Michael S. Epstein, Walter Reinisch, Mariam S. Sauer, Robert Hardi, Mark S. Silverberg
Publikováno v:
Gastrointestinal Endoscopy. 87:677-687.e3
Background and Aims NER1006 is the first 32 fluid ounce (1 L) polyethylene glycol-based bowel preparation. This randomized, multicenter, colonoscopist/central reader-blinded phase 3 non-inferiority trial assessed the efficacy, safety, and tolerabilit
Autor:
Stuart C. Gordon, Rvikumar Vemuru, Mark Eisner, Jay Cowan, James Ehrlich, Alain Ades, Clifford A. Brass, Micheal David Bernstein, Steve Chen, Donald Hillebrand, Donald Wadland, Lyle Shlager, C. Smith, Lou Gelrud, Mark Levstik, Helen Wong, Stephen A. Harrison, Andrew Nelson, Raj Bhandari, David Dies, Mordechai Rabinovitz, Edward A. Galen, B. Freilich, K. Digregorio, Curt Hagendom, Thomas Hargrave, Paul Bermanski, David Maccini, Samuel B. Ho, Ronald Pruitt, Terence Reisman, Thomas Allen, Robert S. Brown, Michael Cox, David Schulman, Ramsey Cheung, Fred Kilby, J. Lynn Cochran, Thomas McDonald, James Thornton, John Jolley, John Serini, Albert D. Min, Fredrich Loura, Lino Deguzman, Luis Marsano, Robert Finkel, Helen S. Te, Michael G Rahmin, Mark Jonas, Kip Lyche, Jean Luc Szpakowski, George Abraham, Alex D. Lee, Pabak Mukhopadhyay, Firdous Siddiqui, Robert Strauss, William Kaplan, Michael Ryan, Eliot Godofsky, Stephen J. Lanspa, Lawton Shick, Jose Franco, Louis Griffel, Rise Stribling, Avanish Aggarwal, Clive Albert, Thomas Rosenfield, Rockford Yapp, Vijay Balan, Arthur Berman, Nezam H. Afdhal, Maurice Cerulli, Paul Yudelman, Robert Herring, Donate Ricci, Michael Henry, Michael Bloom, Daniel Meline, Barry Migicovsky, Peter Varunok, Peter W Gardner, Gerald Siciliano, Natarjan Bala, Craig J. Peine, P. Kwo, Thomas Noble, David F. Stein, Thuan T. Nguyen, Geoffrey Zucker, Julie E Spivack, John Kichner, Robert G. Gish, Michael Fried, Murali Shankar, Norman Gitlin, James E. Nelson, David Hurwich, Darrell Schwertner, Ronald Wasserman, Douglas D. Dalke, Thai Van Pham, Geronimo Sahagun, Norah A. Terrault, Naoky Tsai, Steven Han, Tarek Hassanein, Thomas Sepe, Seth Richter, Howard Paul Monsour, Micheal Lyons, R. Agrawal, Bennett Cecil, Joseph Polito, Douglas Levin, James Srour, Allan Weston, Larry Weprin, Raymond Kenny, Edward Lebovics, Michael Demicco, Terry Box, Kenneth Diamond, Lawrence Kim, Stephen Kelly, Martin Black, Jeffrey Fenyves, Ellen Shaw, Raymond A. Rubin, James E. Cox, Franco Felizarta, John E. Gross, Ira Lobis, David H. Van Thiel, Bonnie Bock, Lawrence Stein, James D. Lewis, Steven Palley, Ronald Rinker, Joanna Ready, Vinod K. Rustgi, Michael Epstein, David H Berman, Gary Matusow, Walid Baddoura, Gerond Lake-Bakaar, John S. Goff, Scott Wiesen, Neil Brodsky, Fredric Regenstein, Arnold Levin, Bhupinder S. Anand, Stephen Esposito, K. Rajender Reddy, Lisa Ozick, Adil E. Wakil, Karl Esrason, Pierre Nader, David Nunes, David Feldman, K. Ganeshappa, Alan Fixelle, Martha Ghosh, Douglas Brouillette, Victor Araya, Hillel Tobias, David Pound, Louis R. Lambiase, S. Lawrence Rothman, Mark J. Murphy, Jonathan David, James Levin, Steve Carlson, Nathan Kam, Michael S. Dragutsky, Trong Nguyen Tuan, Graham Woolf, Whit Knapple, Donna Goldman, Kenneth R. DeVault, Simon Cofrancesco, Mitchell L. Shiffman, Charles Bedard, Paul Y. Kwo, Rodger Perez, Steven L. Flamm, Keith Tolman, Hulya Levendoglu, Timothy Cavacini, Robert Reindollar, Vance VanDrake, Donald M. Jensen, David Winston, Robert A. Levine, Robert Manning, John R. Lake, John J. Santoro, Scott Becker, Mary Pat Pauly, John M. Vierling, Joseph DePasquale, Jorge Herrera, Diana Sylvestre, Natarajan Ravendhran, Mark Smith, Kevin Dye, M. Davis, Frank Klion, Kevin Behrle, Alan Epstein, William Lyles, Brian K. Hudes, Greg Galler, David I. Bernstein, Jonathon Jensen, Jeffery Cooley, Thomas J. Layden, Carl D'Angelo, Fredric D. Gordon, Myron Brand, David Gabbazaideh, Leon Rigberg, Neville R. Pimstone, Jonathan McCone, Ira M. Jacobson, Tim M Jenkins, John W. King, Harry Matossian, William A. Ross, Rudra Rai
Publikováno v:
Hepatology. 46:971-981
This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults wi
Autor:
Douglas Bruce, Michael Demicco, Hamza Kandoussi, Richard Bertz, Philip Wastall, Wen-Lin Luo, Tushar Garimella, Carey Hwang, Reena Wang, Marc Bifano
Publikováno v:
Journal of the International AIDS Society
Introduction : Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (1–6) activity in vitro. Methadone (MET) and buprenorphine (BUP) are opioid medications used to treat opioid addiction; patien
Autor:
Di An, M. Davis, Nezam H. Afdhal, Kris V. Kowdley, Eric Lawitz, John M. Vierling, Robert H. Hyland, Stuart C. Gordon, William T. Symonds, David R. Nelson, Jane K Anderson, R. Hindes, David E. Bernstein, Tarek Hassanein, M.M. Berrey, Israel Crespo, Hadas Dvory-Sobol, Ira M. Jacobson, Efsevia Albanis, Michael Demicco
Publikováno v:
Lancet (London, England). 381(9883)
Summary Background The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and efficacy of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and
Autor:
Dennis M. Grasela, Richard E. Nettles, Apinya Vutikullird, Eric Lawitz, Ellen Chung, Min Gao, Thomas Marbury, Juan Carlos Lopez-Talavera, Ernesto Fuentes, Michael Demicco, Maribel Rodriguez-Torres, Anna Persson, Marc Bifano, Ronald Goldwater
Publikováno v:
Hepatology (Baltimore, Md.). 54(6)
The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multip
Autor:
Tushar Garimella, Reena Wang, Wen-Lin Luo, Philip Wastall, Hamza Kandoussi, Michael Demicco, Robert Bruce, Carey Hwang, Richard Bertz, Marc Bifano
Publikováno v:
Open Forum Infectious Diseases. 1:S346-S347
Publikováno v:
American Journal of Gastroenterology. 110:S631